Product Reports Resources Pricing Login Book a demo

Insitro

Biotech & Life Sciences · San Francisco, United States · Founded 2018

Insitro is a startup operating in the pharmaceutical research and development (R&D) sector, specifically in the area of drug discovery and development. The company uses machine learning and modern biological tools to predict more accurately and earlier which paths are likely to lead to successful medicines. This approach aims to reduce expensive failures that are common in the pharmaceutical R&D process. Insitro's business model is based on integrating machine learning and biology at a large scale to create predictive models. These models are designed to outperform intuition and help avoid dead ends in the drug discovery process. The company's team, composed of scientists, engineers, and drug hunters, works together to generate and leverage data to advance future medicines. The company's clients are likely to be other pharmaceutical companies, healthcare providers, and potentially research institutions that are looking for more efficient and effective ways to discover and develop new drugs. Insitro's revenue model is not explicitly stated, but it's reasonable to assume that it could involve selling their predictive models and data-driven insights to other companies, or partnering with other pharmaceutical companies to co-develop new drugs. In summary, Insitro is a data-driven, integrated drug discovery and development company that uses machine learning and modern biological tools to improve the efficiency and effectiveness of pharmaceutical R&D. Keywords: Drug Discovery, Drug Development, Machine Learning, Biology, Predictive Models, Data-Driven, Pharmaceutical R&D, Integrated, Efficiency, Effectiveness.

Valuation $1–2.5B
Revenue $50–100M
Headcount 100–500
Total funding $500M–1B
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Insitro and the history behind them.

Investors

16 investors on Insitro's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 2 investors entered at this stage

Global footprint

Where Insitro has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States95.8%
🇵🇱 Poland1.9%
🇨🇦 Canada0.9%
🇦🇪 United Arab Emirates0.5%
🏳️ Democratic Republic of the Congo0.5%
Top 5 of 6 shown
Web traffic by country
17K monthly visits
across markets
🇺🇸 United States61.2%
🇮🇳 India7.6%
🇧🇷 Brazil7.1%
🇨🇦 Canada6.5%
🇯🇵 Japan5.3%
Top 5 markets shown

Talent graph

The shape of Insitro's talent

Dealroom maps Insitro's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

34 standout operatorsDealroom-flagged across the org
34 AI specialistsincl. 25 core researchers
257 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Insitro's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$8M patent portfolio · 35 active families

Estimated portfolio value
$8M
0.34% of valuation · 1.6× larger than top peer Zymergen ($5M)
35 active patent families
Where Insitro innovates BioinformaticsComputational biologyHepatocyteLearning modelsLibrary

Where Insitro concentrates vs peers

Each axis is a top-10 topic across Insitro and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Insitro

An AI-synthesized read of the highest-engagement posts about Insitro on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Insitro on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.